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receiving piperacillin-tazobactam (12.3%) versus meropenem
(3.7%).5 Such data should have been discussed. Likewise, no
information is provided on treatment duration or dose, which
may have varied between the 2 groups in the present study.1 Both
factors play a role in the outcome of treatment, especially when
used against multidrug-resistant organisms.6
Interestingly, we previously showed that BSI severity or mor-
tality among spinal cord injury patients over 15 years was not
related to the multidrug-resistant characteristics of the micro-
organism.7 Although our sample size was small (n< 30), a closer
look at the outcome between ESBL-EC (n= 26) and ESBL-KP
(n= 13) did not reveal any statistical difference in terms of mortality
rate (7.7% in each arm). Moreover, the mortality rates were similar
for other ESBL microorganisms (Enterobacter spp,Morganella spp,
and Proteus spp (n=21)), ~ 9.5% (P= .99, data not shown).
In fact, we believe that the findings of Scheuerman et al, which
showed no impact of CTX-M isolates in comparison to other
ESBL genotypes, might support the idea that the type of germ
does not play a major role. Indeed, mortality seems more related
to patient comorbidities and severity of infection, as shown in
Table 2 of the article,1 with significant discrepancies between the
2 groups in terms of length of stay to bacteremia (P= .017),
source of infection (P= .005), ICU ward admission (P< .001) and
underlying cardiovascular disease (P< .001). Moreover, in a
rabbit model of sepsis induced by a multidrug-resistant Klebsiella
pneumoniae, Zhou et al8 showed that mortality was higher for
the rabbits infected by susceptible than those infected with
multidrug-resistant strains.
Overall, the impact of ESBL-KP isolates on mortality rate
might have been overestimated, in the light of the severity of the
patient condition.
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To the Editor—We read with interest the recent article by
Scheuerman et al,1 in which they found that patients with
extended-spectrum-β-lactamase (ESBL) producing Klebsiella
pneumoniae infections had higher 30-day mortality than patients
with ESBL producing Escherichia coli infections. We have recently
published on mortality, readmissions, recurrences, and the benefit
of infectious diseases consultation for patients with various
multidrug resistant organism infections.2,3 We included in our
study patients with various ESBL producing Enterobacteriaceae
infections, among them K. pneumoniae and E. coli. Given the
recent findings of Scheuerman et al, we conducted a retrospective
evaluation to determine the association between ESBL producing
organism (K. pneumoniae or E. coli) and 30-day all-cause mor-
tality at our institution.
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This study was conducted at Barnes-Jewish Hospital, a 1,250-
bed academic medical center in St Louis, Missouri. The study
period was January 1, 2006, to October 1, 2015. We included
patients with positive sterile site and bronchial wash/bronch-
oalveolar lavage cultures for ESBL-producing E. coli and
K. pneumoniae. Sterile sites were defined as bloodstream; pleural,
intra-abdominal, pericardial, cerebrospinal, and synovial fluids;
bone marrow; and surgical specimens collected from lymph
nodes, central nervous system, liver, spleen, kidney, pancreas,
ovary, or vascular tissue. The presence of ESBL production was
assumed based on ceftriaxone, aztreonam, cefotaxime, or cefta-
zidime nonsusceptibility.4 The Washington University School of
Medicine Institutional Review Board approved this study with a
waiver of informed consent.
The primary endpoint was 30-day all-cause mortality. Kaplan-
Meier curves for 30-day all-cause mortality were generated to
compare organism type and significance determined using the
log-rank test. Escherichia coli was used as the reference group for
determining the association between organism and mortality.
Log-log survival plots were used to graphically test the propor-
tional hazards assumption. Factors associated with mortality in
bivariate analysis (P< .20) were entered into a multivariate Cox
proportional hazards model to determine hazard ratios (HR) for
30-day all-cause mortality. All analyses were conducted with SPSS
version 25 software (IBM, Armonk, NY).
In total, 605 patients met the eligibility criteria: 543 with
ESBL E. coli and 62 with ESBL K. pneumoniae. Among patients
with ESBL E. coli, 96 (17.7%) died within 30 days compared to
16 (25.8%) with ESBL K. pneumoniae. In Kaplan-Meier analysis,
mortality was not significantly different between patients infec-
ted with K. pneumoniae and E. coli ESBL organisms (P= 0.12).
Variables retained in the final Cox proportional hazards model are
shown in Table 1. Infection with ESBL-producing K. pneumoniae
was marginally associated with mortality in the final Cox propor-
tional hazards model (hazard ratio [HR], 1.69; 95% confidence
interval [CI], 0.97–2.92; P= .062). Because the number of patients in
the ESBL K. pneumoniae group was small, we performed a post-hoc
power analysis and found that we had only 35.8% power to detect a
significant difference in mortality.
Our results add to the body of literature on differences in
mortality between ESBL-producing K. pneumoniae and E. coli.
Despite the low power of our study, ESBL-producing K. pneu-
moniae was associated with marginally increased risk of 30-day
mortality. Our data are important to add to the literature on this
subject and could be combined with the data of Scheuerman et al
and future studies in a meta-analysis to more definitively deter-
mine the association between ESBL-producing organism type and
mortality. In addition, as demonstrated in our previous study,
infectious disease consultation was associated with reduced
mortality for drug-resistant Enterobacteriaceae infections.
Acknowledgments. The content is solely the responsibility of the authors
and does not necessarily represent the official view of the National Institutes of
Health (NIH).
Financial support. This work was supported by a grant from the
Washington University Institute of Clinical and Translational Sciences
(grant no. UL1TR000448) and by a subaward (no. KL2TR000450) from
the National Center for Advancing Translational Sciences (NCATS) of
the NIH.
Potential conflicts of interest. Dr Kollef was supported by the Barnes-
Jewish Hospital Foundation. All other authors report no conflicts of interest
relevant to this article.
References
1. Scheuerman O, Schechner V, Carmeli Y, et al. Comparison of predictors
and mortality between bloodstream infections caused by ESBL-producing
Escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control
Hosp Epidemiol 2018;39:660–667.
2. Burnham JP, Kwon JH, Olsen MA, Babcock HM, Kollef MH. Readmissions
with multidrug-resistant infection in patients with prior multidrug-
resistant infection. Infect Control Hosp Epidemiol 2018;39:12–19.
3. Burnham JP, Olsen MA, Stwalley D, Kwon JH, Babcock HM, Kollef MH.
Infectious diseases consultation reduces 30-day and 1-year all-cause
mortality for multidrug-resistant organism infections. Open Forum Infect
Dis 2018;5(3):ofy026.
4. Laboratory detection of extended-spectrum β-lactamases (ESBLs). Centers
for Disease Control and Prevention website. https://www.cdc.gov/hai/
settings/lab/lab_esbl.html. Published 2010. Accessed May 30, 2018.
Table 1. Factors Associated with 30-Day All-Cause Mortality in a Cox Propor-
tional Hazards Modela
Risk Factor
Hazard Ratio
(95% CI)
P
Value
Infection with ESBL producing K. pneumoniae
(reference group E. coli)
1.69 (0.97–2.92) .062
Comorbidity
Metastatic cancer 3.20 (1.75–5.82) <.001
HIV/AIDS 6.19 (2.38–15.1) <.001
Cardiovascular disease 2.11 (1.38–3.46) .001
Chronic respiratory failure 0.68 (0.42–1.08) .100
Cirrhosis 4.95 (3.17–7.75) <.001
Leukemia 2.42 (1.34–4.38) .003
Solid organ cancer 2.00 (1.23–3.26) .005
Index hospitalization characteristics
ID consultation 0.37 (0.22–0.60) <.001
Required ICU care during hospitalization 2.87 (1.77–4.64) <.001
APACHE II score >21 2.29 (1.31–3.99) .003
NOTE. HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome;
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; HR,
hazard ratio; ICU, intensive care unit; ID, infectious diseases.
aVariables not retained in final model included admitting service, sex, lymphoma, con-
gestive heart failure, diabetes, solid organ transplant, bone marrow transplant, chronic
kidney disease, and end-stage renal disease.
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